Ernexa Therapeutics (ERNA) Operating Expenses (2009 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Ernexa Therapeutics was $13.78 million, up 28.4% year-over-year; for FY2025, it came in at $9.32 million, down 42.3% from FY2024.

• Annual Operating Expenses has declined for four consecutive years, though with a five-year compound annual growth rate of 5.2% (FY2020 to FY2025).
• In prior years, Ernexa Therapeutics' Operating Expenses was $16.16 million in FY2024 (-22.9%), $20.97 million in FY2023 (-36.9%), $33.22 million in FY2022 (-70.8%) and $113.73 million in FY2021.
• Quarterly Operating Expenses has run from a low of $1.99 million in Q3 2025 to a high of $86.28 million in Q3 2021 over five years.
• On a year-over-year basis, Operating Expenses increased in two of the last eight quarters, with an average decline of 10.6%.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q4 2021, with growth of 286.2%; the weakest was Q3 2022, with a decline of 90.4%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $5.59 million (Q1 2026), $2.09 million (Q4 2025) and $1.99 million (Q3 2025).